Moving Green At The Jump, (Nasdaq: NCEL) Grabs Attention With A Key Shareholder Letter Update

*Sponsored Moving Green At The Jump, (Nasdaq: NCEL) Grabs Attention With A Key Shareholder Letter Update *Get Our Updates Faster—Tap Here To Receive SMS Alerts* November 4th Greetings, Friend! NewcelX Ltd. (Nasdaq: NCEL) tops Tuesday's watchlist as the company just released a shareholder update this morning and is moving green. Take a look: NewcelX CEO Issues Letter to Shareholders Here are some highlights from the letter: Our Inflection Point: Science Advancing Toward Value This is the moment our platform has been built for. Over the coming year, we intend to: Launch a U.S. Phase 2a clinical study in ALS Deliver a toxicity study and prepare to initiate a U.S. Phase 1 clinical study in IsletRx Expand AstroRx® into pipeline indications such as Multiple Sclerosis ("MS") Progress the DOXA platform toward lead-candidate selection These are not incremental steps. They represent the kind of value-creating inflection points that we believe redefine our trajectory. ----- Don't forget, NCEL has a low float with fewer than 6Mn shares outstanding. That means volatility potential could be significantly heightened after today's press release. Take a moment to review my initial (Nasdaq: NCEL) report below and consider this profile for your radar. ----- Advancements in biotechnology are reshaping how we approach complex neurological and metabolic conditions. One innovative company at the forefront is reimagining treatment through a powerful combination of cell-based and small-molecule therapies designed to repair, restore, and revitalize biological function. Its breakthrough work bridges scientific discovery and real-world application, with programs showing potential to transform patient outcomes in areas long considered difficult to treat. As the science matures and clinical progress accelerates, this company stands out as a force quietly redefining what’s possible in modern medicine: *NewcelX Ltd. (Nasdaq: NCEL)* NewcelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. *BREAKING NEWS* NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and Plan of Reorganization, as amended from time to time, dated as of November 4, 2024 (the "Merger Agreement"), by and among NewcelX (f/k/a NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS")), NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. ("Kadimastem"), effective as of October 30, 2025 (the "Merger"). ... ... "This merger unites years of pioneering science in cell therapy and drug discovery under one global platform," said Prof. Michel Revel, Chief Scientific Officer of NewcelX. "NewcelX represents the next step in realizing the promise of regenerative medicine for patients living with amyotrophic lateral sclerosis ("ALS"), diabetes, and other neurodegenerative diseases." Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX said, "With the launch of NewcelX, we have brought together exceptional science and a global leadership team with the potential to change lives. The completion of the merger and the commencement of trading on Nasdaq mark a significant milestone that reflects the trust and confidence of our shareholders and investors, and I am deeply grateful for their support as we take this next step forward together. We are now preparing to initiate our Phase 2a clinical trial of AstroRx® in ALS and to advance the development of IsletRx for the treatment of Type 1 diabetes without the need for lifelong immunosuppression." ... Read the full article here. Newcel X Ltd. Company Breakdown - Transforming The Future Of Medicine With Next-gen Cell Therapies Unique technology platform production of off-the-shelf cell treatments for multiple diseases Platform Technology NewcelX has developed ground-breaking medical applications in regenerative medicine through “off-the-shelf” cell products. Cell therapy represents a new frontier in treating degenerative diseases by replacing, restoring, or repairing malfunctioning cells with healthy, functional ones. The company’s proprietary technology enables the production of functioning cells differentiated from pluripotent stem cells. Using AstroRx®, NewcelX can transplant healthy brain glial cells (astrocytes) to support the survivability of nerve cells, with clinical trials showing promising results in treating ALS. NewcelX has received FDA approval of its IND application for its U.S. multi-site Phase IIa clinical trial of AstroRx® to treat ALS. In addition, NewcelX introduces its differentiation platform technology, IsletRx, which consists of highly purified functional human pancreatic islet cells capable of secreting insulin. IsletRx cells have demonstrated the ability to balance blood sugar levels and maintain them over time, serving as the company’s main candidate for the potential cure of Type 1 diabetes. NewcelX also presents its DOXA platform, an innovative multitarget approach to treating central nervous system (CNS) disorders by addressing key neurophysiological pathways beyond traditional symptomatic management. Unlike conventional therapies that primarily focus on alleviating symptoms, DOXA compounds aim to restore orexin signaling while concurrently modulating neuroinflammatory and metabolic pathways. This approach combines dual orexin receptor activation (OX1R and OX2R) with cathepsin inhibition, offering a comprehensive therapeutic strategy for disorders such as narcolepsy, ALS, and diabetes-related cognitive impairments. Extensive preclinical research supports the potential of DOXA to provide both symptomatic relief and disease-modifying effects. AstroRx® for ALS AstroRx® is an advanced cell therapy product (human healthy Astrocytes, supporting cells for neurons/CNS) designed to slow the progression of ALS by multiple mechanisms of action of nurturing and protecting the neurons in the CNS. Following a successful Phase I/IIa study in 10 ALS patients, the company was granted IND approval to conduct a Phase IIa multi-site clinical trial in the US by the FDA. In addition to ALS, AstroRx® cell product can be beneficial in other neurodegenerative diseases indications, such as Glaucoma and MS, established in POC studies in animal models. NewcelX’s innovative approach is to use fully differentiated astrocytes as a regenerative medicine therapy for ALS – AstroRx® to slow the progression of the disease and improve the patient's life quality and life expectancy. AstroRx® is administered directly into the patient’s spinal cord fluid by a standard intrathecal injection under local anesthesia. Pre-clinical studies in ALS animal models showed that AstroRx® is a safe treatment that provides systemic support to damaged motor neurons, increasing the life expectancy and motor functions. The planned clinical trial follows a first in human phase I/IIa clinical trial previously conducted by the company in Israel, in which AstroRx® was injected into the spinal cord fluid using a standard lumbar puncture procedure. In this phase I/IIa clinical trial NewcelX demonstrated a good safety profile and clinically meaningful decline in the disease progression during the first 3-months follow-up period. IsletRx for Type 1 Diabetes and Insulin-Dependent Diabetes IsletRx represents a breakthrough in cell therapy for diabetes, offering innovative immune protection and long-term blood sugar control. Based on NewcelX’s differentiation platform technology, IsletRx consists of highly purified functional human pancreatic islet cells that secrete insulin and can be produced in large quantities. In preclinical proof-of-concept studies conducted in immunocompetent diabetic mice, IsletRx cells demonstrated the ability to balance blood sugar levels and maintain normal levels over time. IsletRx is produced using the company’s proprietary method, which includes a unique enrichment stage for functionally active cells identified through newly specific cell surface biomarkers. Additionally, IsletRx incorporates a technology platform; it protects the islet cells from the host immune system without the need for potentially toxic immunosuppressive drugs. This technology enables a prolonged therapeutic effect, as demonstrated in preclinical studies. IsletRx is designed to free patients from continuous blood sugar monitoring and repeated insulin injections. The company’s Diabetes Program includes an innovative potential cure currently in preclinical development for Type 1 diabetes in collaboration with iTolerance Inc. The program’s iTOL102 candidate combines NewcelX’s cell therapy product, IsletRx cells, with iTOL-100 microgel designed to achieve local immune tolerance. IsletRx cells are manufactured using a proprietary platform that provides an unlimited supply of highly purified, functional insulin-secreting pancreatic islet cells derived from pluripotent stem cells. Grab Sources And More Here: NCEL Website. Final Notes With the announcement of the Merger above, NCEL has also shared it will have fewer than 6Mn shares outstanding. This means volatility potential could be significantly heightened with so few shares available. With coverage now officially initiated on NewcelX Ltd. (Nasdaq: NCEL), consider watching it closely this week as this game-changing merger news continues to circulate. I'll be back with updates soon. Keep your eyes peeled. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. NewcelX Ltd (NCEL:US) previously changed their company name and symbols from NLS Pharmaceutics AG (NLSP:US) Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 11/03/2025 and ending on 11/04/2025 to publicly disseminate information about (NCEL:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NCEL:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ncel-3puup/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice